MUC1 and cancer: Participants: Estimated enrollment is 8 patients. Type of cells used: Naturally occurring, autologous pDCs and mDCs loaded with tumor lysate and MUC1 and surviving PepTivators. Primary objective: To investigate the hypothesis that pDCs and mDCs are optimal for vaccines to combat cancer. To investigate the hypothesis that the combination of mDC and pDC may induce stronger anti-tumor immune responses as compared to pDC or mDC alone, or moDC.